Abstract:Following the consolidation of therapeutic proteins in the fight against cancer, autoimmune, and neurodegenerative diseases, recent advancements in biochemistry and biotechnology have introduced a host of next-generation biotherapeutics, such as CRISPR-Cas nucleases, stem and car-T cells, and viral vectors for gene therapy. With these drugs entering the clinical pipeline, a new challenge lies ahead: how to manufacture large quantities of high-purity biotherapeutics that meet the growing demand by clinics and biotech companies worldwide. The protein ligands employed by the industry are inadequate to confront this challenge: while featuring high binding affinity and selectivity, these ligands require laborious engineering and expensive manufacturing, are prone to biochemical degradation, and pose safety concerns related to their bacterial origin. Peptides and pseudopeptides make excellent candidates to form a new cohort of ligands for the purification of next-generation biotherapeutics. Peptide-based ligands feature excellent target biorecognition, low or no toxicity and immunogenicity, and can be manufactured affordably at large scale. This work presents a comprehensive and systematic review of the literature on peptide-based ligands and their use in the affinity purification of established and upcoming biological drugs. A comparative analysis is first presented on peptide engineering principles, the development of ligands targeting different biomolecular targets, and the promises and challenges connected to the industrial implementation of peptide ligands. The reviewed literature is organized in (i) conventional (α-)peptides targeting antibodies and other therapeutic proteins, gene therapy products, and therapeutic cells; (ii) cyclic peptides and pseudo-peptides for protein purification and capture of viral and bacterial pathogens; and (iii) the forefront of peptide mimetics, such as β-/γ-peptides, peptoids, foldamers, and stimuli-responsive peptides for advanced processing of biologics.

Protein Grafting Techniques: From Peptide Epitopes to Lasso‐Grafted Neobiologics

Grafting of Protein-Protein Interaction Epitope.

Automated Flow Peptide Synthesis Enables Engineering of Proteins with Stabilized Transient Binding Pockets

Lasso Peptides: Heterologous Production and Potential Medical Application

Grafting of Protein-Protein Binding Sites

Synthesis of Well-Defined Protein–polymer Conjugates for Biomedicine

Nature-inspired protein ligation and its applications

Biodynamical Implications of Grafting Position Alteration in Engineered Mimics of Parkinson's Inhibitor MCoCP4

Automated Peptide Synthesizers and Glycoprotein Synthesis

Engineered protein nanodrug as an emerging therapeutic tool

Peptides and pseudopeptide ligands: a powerful toolbox for the affinity purification of current and next-generation biotherapeutics

Enhancing Cellular Uptake of Native Proteins through Bio-Orthogonal Conjugation with Chemically Synthesized Cell-Penetrating Peptides

Genetic Functionalization of Protein-Based Biomaterials via Protein Fusions

Recent advances in antibody glycoengineering for the gain of functions

Plant glycoengineering for designing next-generation vaccines and therapeutic proteins

Merging Flow Synthesis and Enzymatic Maturation to Expand the Chemical Space of Lasso Peptides

Engineered Protein-G variants for plug-and-play applications

Gene Delivery From Granular Scaffolds for Tunable Biologics Manufacturing

Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery

A Novel Gene Synthesis Platform for Designing Functional Protein Polymers

Glycopeptides as versatile tools for glycobiology